1.How Many Valid Measurements Are Necessary to Assess Liver Fibrosis Using FibroScan(R) in Patients with Chronic Viral Hepatitis? An Analysis of Subjects with at Least 10 Valid Measurements.
Hui Won JANG ; Seung Up KIM ; Jun Yong PARK ; Sang Hoon AHN ; Kwang Hyub HAN ; Chae Yoon CHON ; Young Nyun PARK ; Eun Hee CHOI ; Do Young KIM
Yonsei Medical Journal 2012;53(2):337-345
PURPOSE: Using FibroScan(R) to obtain a reliable liver stiffness measurement (LSM) may require more than 10 valid measurements (VMs), according to the manufacturer's recommendations. However, this requirement lacks scientific evidence in support thereof. We investigated the minimal number of VMs required to assess liver fibrosis without significant loss of accuracy in patients with chronic hepatitis B (CHB) and C (CHC) and predictors of discordance between LSM and liver biopsy (LB). MATERIALS AND METHODS: Between January 2005 and December 2009, we prospectively enrolled 182 patients with CHB and 68 patients with CHC who were to undergo LB and LSM before starting antiviral treatment. Only LSMs with at least 10 VMs were considered reliable. The Batts and Ludwig scoring system was used for histologic assessment. RESULTS: The mean age and body mass index were 46.0 years and 23.4 kg/m2 in patients with CHB and 49.7 years and 23.1 kg/m2 in those with CHC, respectively. The median elasticity scores from the first 3, first 5, and all VMs taken significantly predicted fibrosis stages > or =F2 and F4 (all p<0.05) without significant differences (all p>0.05 by DeLong's method). Alanine aminotransferase (ALT) was the only predictor of discordance in fibrosis stage as estimated by the median elasticity score from the first 3 VMs and by LB in patients with CHB, whereas no significant predictor was identified in those with CHC. CONCLUSION: After comparison of patients who had more than 10 valid measurements for LSM, three VMs may be enough to assess liver fibrosis using LSM without significant loss of accuracy in patients with CHC and patients with CHB. However, ALT should be considered when interpreting LSM for patients with CHB.
Adult
;
Alanine Transaminase/metabolism
;
Female
;
Hepatitis B, Chronic/*complications/metabolism
;
Humans
;
Liver/metabolism/pathology
;
Liver Cirrhosis/*diagnosis/etiology/metabolism
;
Male
;
Middle Aged
;
Prospective Studies
2.Prospect of liver fibrosis.
Chinese Journal of Hepatology 2009;17(1):5-6
3.Liver transplantation for acute-on-chronic liver failure from erythropoietic protoporphyria.
Pyoung Jae PARK ; Shin HWANG ; Young Il CHOI ; Young Dong YU ; Gil Chun PARK ; Sung Won JUNG ; Sam Youl YOON ; Gi Won SONG ; Tae Yong HA ; Sung Gyu LEE
Clinical and Molecular Hepatology 2012;18(4):411-415
Erythropoietic protoporphyria (EPP) is an inherited disorder of the heme metabolic pathway that is characterized by accumulation of protoporphyrin in the blood, erythrocytes, and tissues, and cutaneous manifestations of photosensitivity, all resulting from abnormalities in ferrochelatase (FECH) activity due to mutations in the FECH gene. Protoporphyrin is excreted by the liver, and excess protoporphyrin leads to cholelithiasis with obstructive episodes and chronic liver disease, finally progressing to liver cirrhosis. Patients with end-stage EPP-associated liver disease require liver transplantation. We describe here a 31-year-old male patient with EPP who experienced acute-on-chronic liver failure and underwent deceased-donor liver transplantation. Surgical and postoperative care included specific shielding from exposure to ultraviolet radiation to prevent photosensitivity-associated adverse effects. The patient recovered uneventfully and was doing well 24 months after transplantation. Future prevention and treatment of liver disease are discussed in detail.
Acute Disease
;
Adult
;
End Stage Liver Disease/etiology/pathology/*therapy
;
Ferrochelatase/genetics/metabolism
;
Humans
;
Liver Cirrhosis/diagnosis
;
*Liver Transplantation
;
Male
;
Mutation
;
Protoporphyria, Erythropoietic/complications/*diagnosis/pathology
4.A Case of Bacteremia by Neisseria gonorrhoeae Coincident with Massive Hemorrhage of Esophageal Varices.
Dahae WON ; Dongheui AN ; Mi Na KIM ; Young Sang LEE
The Korean Journal of Laboratory Medicine 2011;31(2):118-121
A 42-yr-old man with hepatitis B virus associated liver cirrhosis was admitted to the emergency room because of multiple seizures, a history of chills and myalgia over the previous 2 weeks, and 3 days of melena. He was febrile with a temperature of 38.0degrees C. There were no symptoms and signs related to the genitourinary system, skin, or joints. Three sets of blood cultures were obtained and oxidase-positive, gram-negative diplococci were detected after 25.9-26.9 hr of incubation in all aerobic vials. The organism was positive for catalase and oxidase, and was identified as Neisseria gonorrhoeae, using a Vitek Neisseria-Haemophilus Identification card (bioMerieux Vitek, Inc., USA). Further, 16S rRNA sequencing of this isolate revealed a 99.9% homology with the published sequence of N. gonorrhoeae strain NCTC 83785 (GenBank Accession No. NR_026079.1). Acute bleeding by variceal rupture seems to be a likely route of introduction of N. gonorrhoeae from the mucosa into the blood. To the best of our knowledge, this is the first case of gonococcal bacteremia in Korea.
Adult
;
Bacteremia/complications/*diagnosis/microbiology
;
Catalase/metabolism
;
Esophageal and Gastric Varices/complications/*diagnosis
;
Gastrointestinal Hemorrhage/*etiology
;
Gonorrhea/complications/*diagnosis/microbiology
;
Humans
;
Ligation
;
Liver Cirrhosis/diagnosis
;
Male
;
Neisseria gonorrhoeae/genetics/*isolation & purification
;
Oxidoreductases/metabolism
;
RNA, Ribosomal, 16S/chemistry/genetics
;
Sequence Analysis, DNA
5.A Case of Breast Cancer in a Male Patient with Cryptogenic Cirrhosis.
Su Rin SHIN ; Myung Seok LEE ; Sang Hoon PARK ; Jong Soo CHOI ; Kyung Min LEE ; Jin Bae KIM ; Hyeong Su KIM ; Jeong Won KIM
The Korean Journal of Gastroenterology 2012;60(3):182-185
Breast cancer is a rare disease in men. We report a case of 53-year-old obese male, with known cryptogenic cirrhosis and hepatocellular carcinoma, presenting a tender mass on left breast. He was diagnosed with invasive intraductal carcinoma, which was consistent with a sporadic lesion. On the basis of previous literatures, obesity can be regarded as a cause for breast cancer even in men. However, there has been inconsistent data about link between liver cirrhosis and male breast cancer, which can be due to heterogenity in the etiology of cirrhosis. Through this case, it can be postulated that the risk for male breast cancer may vary according to the etiology of cirrhosis.
Breast Neoplasms, Male/*etiology/secondary/ultrasonography
;
Carcinoma, Hepatocellular/diagnosis/pathology
;
Humans
;
Immunohistochemistry
;
Liver Cirrhosis/complications/*diagnosis/pathology
;
Liver Neoplasms/diagnosis/pathology
;
Male
;
Middle Aged
;
Receptors, Estrogen/metabolism
;
Tomography, X-Ray Computed
6.A Case of Liver Fibrosis with Splenomegaly after Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer.
Gu Hyum KANG ; Hee Seok MOON ; Eaum Seok LEE ; Seok Hyun KIM ; Jae Kyu SUNG ; Byung Seok LEE ; Hyun Yong JEONG ; Heon Young LEE ; Dae Young KANG
Journal of Korean Medical Science 2013;28(12):1835-1838
Previous studies reported that oxaliplatin is associated with sinusoidal obstruction syndrome. However few reports on oxaliplatin induced liver fibrosis are found in the literature. Furthermore pathogenesis of liver fibrosis is not well known. We report a case of 45-yr-old Korean man in whom liver fibrosis with splenomegaly developed after 12 cycles of oxaliplatin based adjuvant chemotherapy for colon cancer (T4N2M0). Thorough history taking and serological examination revealed no evidence of chronic liver disease. Restaging CT scans demonstrated a good response to chemotherapy. Five month after chemotherapy, he underwent right hepatectomy due to isolated metastatic lesion. The liver parenchyma showed diffuse sinusoidal dilatation and centrilobular vein fibrosis with necrosis without steatosis. We could conclude that splenomegaly was due to perisinusoidal liver fibrosis and liver cell necrosis induced portal hypertension by oxaliplatin. In addition, to investigate the pathogenesis of liver fibrosis, immunohistochemical stains such as CD31 and alpha-smooth muscle actin (alpha-SMA) were conducted with control group. The immunohistochemical stains for CD31 and alpha-SMA were positive along the sinusoidal space in the patient, while negative in the control group. Chemotherapy with oxaliplatin induces liver fibrosis which should be kept in mind as a serious complication.
Actins/metabolism
;
Antigens, CD31/metabolism
;
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
;
Camptothecin/*analogs & derivatives/therapeutic use
;
Chemotherapy, Adjuvant
;
Colonic Neoplasms/*drug therapy
;
Fluorouracil/therapeutic use
;
Humans
;
Hypertension, Portal/etiology
;
Immunohistochemistry
;
Leucovorin/therapeutic use
;
Liver Cirrhosis/*diagnosis/etiology/pathology
;
Liver Neoplasms/secondary/surgery
;
Male
;
Middle Aged
;
Organoplatinum Compounds/*administration & dosage/adverse effects/therapeutic use
;
Splenomegaly/*diagnosis/etiology
;
Thrombocytopenia/etiology
;
Tomography, X-Ray Computed
7.The relationship between hemostatic changes in liver cirrhosis patients with different degrees of liver lesions in reference to Child-Pugh scores.
Yu-Long CONG ; Yu-Xiang WEI ; Li-Wen ZHANG ; Zong-Jian YIN ; Jie BAI
Chinese Journal of Hepatology 2005;13(1):31-34
OBJECTIVETo investigate the relationship between hemostatic changes in liver cirrhosis patients with different degrees of their liver lesions.
METHODSForty-three patients (35 men, 8 women; age: 25 to 71 yr) with liver cirrhosis were divided into three subgroups (A, B, and C) on the basis of Child-Pugh classification. Among the patients, 13 were classified as Child-Pugh class A, 15 were class B, 15 were class C. 16 healthy individuals served as controls. A series of hemostatic tests and parameters including prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen (Fib), factors II, V, VII, VIII, IX, X, vWF assay, antithrombin-III (AT-III), protein C (PC), D-dimer, tissue plasminogen activator antigen (t-PA), plasminogen activator inhibitor activity (PAI) were performed on 43 patients and the 16 healthy controls.
RESULTSPT and APTT were progressively prolonged from A to B and then to C. In comparison to the controls there was a significant difference. Fibrinolytic activity and the activities of factors II, V, VII, IX, X were progressively decreased from A to B and then to C. In comparison to the controls there was a significant difference . AT-III and PC activity were progressively decreased from A to B and then to C. In comparison to the controls there was a significant difference. D-dimer and t-PA-antigen were progressively increased from A to B and then to C. In comparison to the controls there was significant difference. PAI activity did not display significant changes in the four groups.
CONCLUSIONWe found that there is a close relationship between the severity of cirrhosis and the hemostatic changes. Because the deterioration of the coagulation function and increasing fibrinolytic activity parallel the severity of liver cirrhosis, adequate treatment for cirrhotic bleeding should not only correct the coagulation defects, but also lower the increased fibrinolytic activity.
Adult ; Aged ; Antithrombins ; metabolism ; Blood Coagulation Factors ; metabolism ; Female ; Fibrinogen ; metabolism ; Hemostasis ; Hepatitis B, Chronic ; blood ; complications ; Humans ; Liver Cirrhosis ; blood ; diagnosis ; etiology ; Male ; Middle Aged ; Prothrombin Time ; Severity of Illness Index
8.Long-term decreased portal pressure in cirrhotic patients with portal hypertension: reality or dream?.
Chinese Journal of Hepatology 2009;17(4):246-248
Animals
;
Antihypertensive Agents
;
therapeutic use
;
Esophageal and Gastric Varices
;
complications
;
prevention & control
;
Gastroscopy
;
Hepatic Stellate Cells
;
metabolism
;
Humans
;
Hypertension, Portal
;
diagnosis
;
etiology
;
therapy
;
Liver Cirrhosis
;
complications
;
Portasystemic Shunt, Transjugular Intrahepatic